Rho Capital Partners Inc Cara Therapeutics, Inc. Transaction History

Rho Capital Partners Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $0 - $0	0 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$11.55 - $16.06 $17.3 Million - $24.1 Million	-1,499,058 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$12.38 - $29.19 $13 Million - $30.6 Million	-1,050,000 Reduced 41.19%	1,499,058 $21.4 Million
Q1 2021 May 13, 2021	SELL	$15.07 - $21.71 $3.77 Million - $5.43 Million	-250,000 Reduced 8.93%	2,549,058 $55.3 Million
Q2 2020 Aug 07, 2020	SELL	$12.39 - $17.33 $4.88 Million - $6.83 Million	-393,999 Reduced 12.34%	2,799,058 $47.9 Million
Q3 2019 Nov 12, 2019	SELL	$18.28 - $26.91 $1.37 Million - $2.02 Million	-75,000 Reduced 2.29%	3,193,057 $58.4 Million
Q2 2019 Aug 13, 2019	SELL	$17.68 - $21.57 $5.3 Million - $6.47 Million	-300,000 Reduced 8.41%	3,268,057 $70.3 Million
Q2 2017 Aug 07, 2017	BUY	N/A	3,568,057	3,568,057 $54.9 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.1M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Rho Capital Partners Inc, based on Form 13F filings with the SEC.

Stay updated on Rho Capital Partners Inc with notifications on news.